Pro 2013-018 (Jianfeng Group's Announcement on Corporate Bond Issuance in 2013)-2
Release time:
2020-08-05
6 , Placing
The lead underwriter will place all valid subscriptions based on the results of the offline inquiry, and the amount of the placement received by institutional investors will not exceed the corresponding maximum subscription amount in their valid subscriptions. The placement is based on the following principles: bookkeeping and filing according to the investor's subscription rate from low to high, the subscription amount is accumulated according to the subscription rate from low to high, and the highest subscription rate corresponding to the total amount of the bond issue is recognized as the issue rate when the accumulated amount exceeds or is equal to the total amount of the bond issue.
In this placement process, investors whose subscription interest rate is below the final issue interest rate will be placed in accordance with the principle of price priority; in the case of the same subscription interest rate, the sponsor (lead underwriter) has the right to decide long-term cooperation Investors are given priority. At the same time, the issuer and the lead underwriter have the right to determine the final placement results of the bonds.
7 , Funds Transfer
Investors who receive the placement shall pay the subscription money in a timely manner according to regulations. The subscription money shall be paid in 201 3 6 7 ( T 2 ) 16:00 before is transferred in full to the receiving bank account designated by the sponsor (lead underwriter). Please indicate the words "Investor Short" and "Jianfeng Group Corporate Bond Subscription Fund " when making the payment, and fax the payment voucher to the sponsor (lead underwriter).
Collection Account Name |
Zhejiang Securities Co., Ltd. |
Collection Account Account |
1202020629900012522 |
Collection Account Opening Bank |
Industrial and Commercial Bank of China Hangzhou Hushu Sub-branch |
Collection Bank Address |
Hangzhou Gongshu District Hushu South Road 377 |
City Exchange Number |
206 |
large payment system line number |
102331002069 |
receiving bank contact |
Chen Li, Guo Jian |
collection Bank Contact Phone |
0571-88377080 , 88377084 |
8 , Online Issuance Registration
Sponsor (Lead Underwriter) According to the Online Issuance Results, the registration data issued offline shall be submitted to the Shanghai Stock Exchange in the form of written and electronic data before the 10:30 on the# of the 201 3 April 13 day (T 3 day). At the same time, electronic data shall be generated as required and submitted to the registration company for registration.
9 , default recognition purchase processing
pair failed to 185 on 201 3 July 7 ( T 2 ) 1 6: investors who have paid their subscriptions in full before 00 will be deemed to have defaulted on the subscription and the sponsor (lead underwriter) has the right to cancel their subscriptions. The sponsor (lead underwriter) has the right to dispose of all the bonds under the 201 offer of the defaulting investor , and has the right to further pursue the legal liability of the defaulting investor in accordance with the law.
, Risk Disclosure
Issuer and Sponsor (Lead Underwriter) have fully disclosed the possible risks involved in this issue on Known Scope . For detailed risk disclosure terms, please refer to "Zhejiang Jianfeng Group Co., Ltd. Public Issuance of Corporate Bonds (Phase I) Prospectus".
6 , Subscription Fee
No commission, transfer fee, stamp duty and other fees will be charged to investors for this issue.
7 , Issuer and Sponsor (Lead Underwriter)
Fa Line : Zhejiang Jianfeng Group Co., Ltd.
Registered Address: Wujiang East Road, Jinhua City, Zhejiang Province 88
Lian Department : Zhu Jianwei, Fu Zhijian
Tel: 0579-82320582 , 82303537
Fax: 0579-82320582
Postal Code: 321000
sponsor (lead underwriter): Zhejiang securities co., ltd.
registered address: Hangzhou hangda road 274
Lian department : Yu Jianxia , Hu Fangchao
Consultation Tel: 0571-8790 1941 , 8790 3138 ;
Purchase Fax: 0571-87902749 , 87903769
Postal Code: 310007
(this page has no text and is the cover chapter page of Zhejiang Jianfeng Group Co., Ltd. 201 3 Corporate Bonds (Phase I) Issuance Announcement )
Issuer: Zhejiang Jianfeng Group Co., Ltd.
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11